Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation
We recommend
Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab
The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation. What is the current reimbursement situation in key indications? We summarize in the following brief overview.
Doc. Miloslav Salavec: We Still Encounter Delayed Initiation of Biological Treatment in AD and Many Other Diagnoses
Not all patients with atopic dermatitis (AD) who are indicated for biological treatment with…
Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years
Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis…
Articles on this topic
What is new in the treatment of atopic dermatitis and how are comorbidities affecting it?
Allergic rhinitis, conjunctivitis, bronchial asthma, or autoimmune diseases like alopecia,…
Meta-analysis of the efficacy and safety of dupilumab in the treatment of atopic dermatitis in children and adults
Moderate to severe atopic dermatitis (AD) is accompanied by strong inflammatory processes that…
Infographic and Commentary from Practice: Reasons and Pathways for Patients to Biological Treatment of Asthma
For asthma patients with the most severe forms of the disease to access targeted biological…
Efficacy and Safety of Dupilumab in the Treatment of Severe Asthma Insufficiently Controlled by Standard Therapy – Current Clinical Practice Data
If severe bronchial asthma with type 2 inflammation is insufficiently controlled by combined…
Targeted Treatment of Children and Adolescents with Severe AD – Case Studies
The results of therapy with dupilumab in children and adolescents with severe forms of atopic dermatitis...
Long-term Safety of Dupilumab in Adult Patients with Moderate to Severe Atopic Dermatitis
Moderate to severe atopic dermatitis (AD) often requires systemic therapy. The long-term…
Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps
The authors of a meta-analysis of nine randomized controlled trials comparing dupilumab,…
Dupilumab Improves Skin and Systemic Symptoms of Atopic Dermatitis
A clinical study conducted in the USA and Canada demonstrated the efficacy of dupilumab in…
Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?
Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the…
Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years
Dupilumab is now fully covered by public health insurance for pediatric patients from 6 years…
1
2
Subscribe
E-courses on this topic
Most read on this topic
- Skin conditions in patients with inflammatory bowel diseases
- Asthma bronchiale in the context of internal medicine
- Dupilumab Now Covered for Atopic Dermatitis in Children Older Than 6 Years
- What is new in the treatment of atopic dermatitis and how are comorbidities affecting it?
- Comparison of Biologics in the Treatment of Chronic Rhinosinusitis with Nasal Polyps
- Infographic and Commentary from Practice: Reasons and Pathways for Patients to Biological Treatment of Asthma
Journal on this topic
Related topic